Walleye Trading
AMLX icon

Walleye Trading’s Amylyx Pharmaceuticals AMLX Stock Holding History

Walleye Trading’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,500
Closed -$90.6K – 4084
2025
Q4 		$90.6K Buy
+7,500
New +$102K ﹤0.01% 3779
2025
Q1 		– Sell
-6,800
Closed -$25.7K – 4010
2024
Q4 		$25.7K Buy
+6,800
New +$32K ﹤0.01% 3914
2024
Q2 		– Sell
-22,500
Closed -$63.9K – 4228
2024
Q1 		$63.9K Sell
22,500
-6,400
-22% -$83.7K ﹤0.01% 3936
2023
Q4 		$425K Sell
28,900
-12,000
-29% -$184K ﹤0.01% 3211
2023
Q3 		$749K Buy
40,900
+30,400
+290% +$643K ﹤0.01% 2608
2023
Q2 		$226K Buy
10,500
+2,500
+31% +$67.5K ﹤0.01% 3345
2023
Q1 		$235K Buy
8,000
+1,500
+23% +$52.1K ﹤0.01% 3393
2022
Q4 		$240K Buy
+6,500
New +$231K ﹤0.01% 3428
2022
Q3 		– Sell
-10,000
Closed -$193K – 4991
2022
Q2 		$193K Buy
+10,000
New +$119K ﹤0.01% 3703

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Walleye Trading's AMLX Position: Q1 2026 in Review

Walleye Trading sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 2,825 shares — an estimated $34.1K sold.

Walleye Trading first reported a position in AMLX in Q2 2022 and held it in 5 quarters. The position peaked at $527K in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Walleye Trading reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 2,825 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $34.1K.
  • Walleye Trading first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Walleye Trading's Amylyx Pharmaceuticals position peaked at $527K in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.